Overview

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Status:
Recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Bristol-Myers Squibb
National Cancer Institute (NCI)
National Institutes of Health (NIH)
The Foundation for Barnes-Jewish Hospital

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Gemcitabine
Nivolumab
Paclitaxel